Assistant
Ask
Navigate
Command

Bristol-Myers Squibb Co. BMY

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, hematology, immunology, and cardiovascular disease. Key marketed products include Opdivo, Eliquis, Revlimid, and Yervoy, addressing serious diseases with significant unmet medical needs worldwide. The company is headquartered in Princeton, New Jersey.

Key ratios
FreeCashFlowOnSale TTM 0.27
FreeCashFlowOnSale 2025 0.27
FreeCashFlowOnSale 2024 0.29
FreeCashFlowOnSale 2023 0.28
NetIncomeMargin TTM 0.15
NetIncomeMargin 2025 0.15
NetIncomeMargin 2024 -0.19
NetIncomeMargin 2023 0.18
ReturnOnAssets TTM 0.1
ReturnOnAssets 2025 0.1
ReturnOnAssets 2024 0.07
ReturnOnAssets 2023 0.05
ReturnOnEquity TTM 0.4
ReturnOnEquity 2025 0.4
ReturnOnEquity 2024 -0.39
ReturnOnEquity 2023 0.27
Recent news
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma 2026-06-02 · Bristol Myers Squibb
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) 2026-06-01 · Bristol Myers Squibb
An unhandled error has occurred. Reload 🗙